Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Antibody Drug Targets Toxic Amyloid Oligomers from Alzheimer’s Disease with Dr. Eric Siemers Acumen Pharma TRANSCRIPT
Download PDFNov 25, 2024
Dr. Eric Siemers, Medical Officer at Acumen Pharma, is developing a monoclonal antibody called sabirnetug that targets a specific toxic form of amyloid beta, Aβ oligomers. These oligomers are now believed to be a key driver of neuronal damage in Alzheimer's disease. The drug is in phase 2 clinical trials to evaluate its ability to slow cognitive decline in early-stage Alzheimer's patients and demonstrate the accuracy of biomarkers in identifying pathology before symptoms appear.
Eric explains, "We've identified, and this is a monoclonal antibody, a monoclonal antibody with a unique mechanism of action in that it targets what are called Aβ oligomers. And without going into all the details, these Aβ oligomers are now really felt to be the toxic species, the ones that cause the neurons to die, and the two drugs that have recently gotten approval sort of indirectly get at those toxic species, maybe one more than the other. But in our case, we're directly targeting what we think is the most toxic species. And so the progress in the field is wonderful, and nobody can say that it's not, or take anything away from that, but nobody's cured the disease either. Now we know we've got a toehold, we know an approach, and Acumen is using an antibody because of this unique target. We think of it as a next-generation treatment for Alzheimer's disease."
"We've known about these Alzheimer's plaques for a long time, but what's more recent is understanding some of these intermediate species. And so these Aβ oligomers we target are oligo, meaning a few. So, anywhere from 2 to 200 of these Aβ stuck together. The Aβs are basically inherently sticky. And so the things we're most interested in are probably 10 of the Aβ together up to say 50, which seems to be the sweet spot."
#AcumenPharmaceuticals #Alzheimers #ALZ #EndALZ #Sabirnetug #DrugDevelopment
